Biofabrication of a PLGA-TCP-based porous bioactive bone substitute with sustained release of icaritin

Xin Hui Xie, Xin Luan Wang, Ge ZHANG, Yi Xin He, Yang Leng, Ting Ting Tang, Xiaohua Pan, Ling Qin*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Abstract

A phytomolecule, icaritin, has been identified and shown to be osteopromotive for the prevention of osteoporosis and osteonecrosis. This study aimed to produce a bioactive poly (l-lactide-co-glycolide)-tricalcium phosphate (PLGA-TCP)-based porous scaffold incorporating the osteopromotive phytomolecule icaritin, using a fine spinning technology. Both the structure and the composition of icaritin-releasing PLGA-TCP-based scaffolds were evaluated by scanning electron microscopy (SEM). The porosity was quantified by both water absorption and micro-computed tomography (micro-CT). The mechanical properties were evaluated using a compression test. In vitro release of icaritin from the PLGA-TCP scaffold was quantified by high-performance liquid chromatography (HPLC). The attachment, proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) on the composite scaffold were evaluated. Both an in vitro cytotoxicity test and an in vivo test via muscular implantation were conducted to confirm the scaffold's biocompatibility. The results showed that the PLGA-TCP-icaritin composite scaffold was porous, with interconnected macro- (about 480μm) and micropores (2-15μm). The mechanical properties of the PLGA-TCP-icaritin scaffold were comparable with those of the pure PLGA-TCP scaffold, yet was spinning direction-dependent. Icaritin content was detected in the medium and increased with time. The PLGA-TCP-icaritin scaffold facilitated the attachment, proliferation and osteogenic differentiation of BMSCs. In vitro cytotoxicity test and in vivo intramuscular implantation showed that the composite scaffold had no toxicity with good biocompatibility. In conclusion, an osteopromotive phytomolecule, icaritin, was successfully incorporated into PLGA-TCP to form an innovative porous composite scaffold with sustained release of osteopromotive icaritin, and this scaffold had good biocompatibility and osteopromotion, suggesting its potential for orthopaedic applications.

Original languageEnglish
Pages (from-to)961-972
Number of pages12
JournalJournal of Tissue Engineering and Regenerative Medicine
Volume9
Issue number8
DOIs
Publication statusPublished - 1 Aug 2015

Scopus Subject Areas

  • Medicine (miscellaneous)
  • Biomaterials
  • Biomedical Engineering

User-Defined Keywords

  • Biocompatibility
  • Cytotoxicity
  • Icaritin
  • Osteogenesis
  • Poly(l-lactide-co-glycolide)/tricalcium phosphate
  • Scaffold

Fingerprint

Dive into the research topics of 'Biofabrication of a PLGA-TCP-based porous bioactive bone substitute with sustained release of icaritin'. Together they form a unique fingerprint.

Cite this